immixbio.com (IMMX) - Margin dodolan reged

Simbol resmi perusahaan immixbio.com (IMMX)

Immix Biopharma, Inc. (IMMX) relies on the stable US legal framework and streamlined biomaterial logistics for its research. This GURU.Markets chart, analyzed by gross profit margin, reflects efficiency dynamics where the 0.00 mark captures this metric. However, a narrow development portfolio creates a critical dependency on clinical trial outcomes and the availability of external funding.

Immix (IMMX) - Margin reged saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan Immix (IMMX)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:Immix Biopharma, Inc.
Produk mawa merek Immix Biopharma Inc.

Investors must balance operating expenses against the potential for return on capital, particularly given the development of NXC-201 CAR-T therapy and the interest in the acquisition of Immix Biopharma (IMMX) by industry behemoths. The gross margin distribution analysis on GURU.Markets, with a current value of 0.00, demonstrates the portion of revenue remaining after direct costs, which determines the fundamental stability of the business and the efficiency of production cost management.

Pesaing utama